NEW YORK (GenomeWeb News) – Biopharmaceutical services and clinical research organization Quintiles today said that it has acquired genomic services provider Expression Analysis.
The acquisition is intended to further Quintiles' push into personalized medicine. Among the services provided by privately held Expression Analysis are whole genome sequencing, gene expression analysis, and genotyping. Among the platforms it uses are Affymetrix's GeneChip; Agilent's Sure Select; Fluidigm's Access Arrays; Illumina's BeadChip, iScan, Genome Analyzer, and HiSeq; RainDance Technologies' RDT 1000; and Pacific Biosciences' PacBio RS. The firm also has a CLIA lab.
Thomas Wollman, SVP of Quintiles Global Laboratories, said in a statement that the deal is "another step forward in our efforts to bring personalized medicine into mainstream drug development."
Terms of the acquisition were not disclosed. Both firms are based in Research Triangle Park, NC.
Last year Quintiles purchased the BioServices Division of proteomics technologies firm Advion, and it partnered with UK firm Population Genetics Technologies aimed at incorporating genomic testing into mainstream drug development.
It also has an alliance with London Genetics focused on providing biomarker and pharmacogenomics consulting and services to biopharmaceutical firms and a companion diagnostics alliance with Dako.